Therini Bio's first in-human dosing for Alzheimer's therapeutic and new chair of board 18-May-2023 By Liza Laws A company focusing on developing fibrin-targeted therapies to treat inflammatory neurodegenerative and retinal diseases announced the initiation of dosing for its lead asset THN391Monday (May 15) .